There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > ErbB3


ErbB3 Molecule Information

Name:Receptor tyrosine-protein kinase erbB-3
Target Synonym:ERBB3;Receptor tyrosine-protein kinase erbB-3;HER3;Tyrosine kinase-type cell surface receptor HER3;Proto-oncogene-like protein c-ErbB-3
Number of Launched Drugs:0
Number of Drugs in Clinical Trials:26
Lastest Research Phase:Phase ?

ErbB3 Protein Product ListCompare or Buy

ErbB3 Part of Bioactivity data

Biotinylated Human ErbB3, His,AvitagBiotinylated Human ErbB3, His,Avitag (Cat. No. ER3-H82E6) ELISA bioactivity

Immobilized Biotinylated Human ErbB3, His,Avitag (Cat. No. ER3-H82E6) at 1 μg/mL (100 μL/well) on Streptavidin (Cat. No. STN-N5116) precoated (0.5 μg/well) plate, can bind Human NRG1 Beta 1, Fc Tag (Cat. No. NR1-H5268) with a linear range of 0.5-8 ng/mL (QC tested).

Mouse ErbB3, His TagMouse ErbB3, His Tag (Cat. No. ER3-M52H5) ELISA bioactivity

Immobilized Mouse ErbB3, His Tag (Cat. No. ER3-M52H5) at 2 μg/mL (100 μL/well) can bind Human NRG1 Beta 1, Fc Tag (Cat. No. NR1-H5268) with a linear range of 0.5-8 ng/mL (QC tested).

ErbB3 Molecule Synonym Name


ErbB3 Molecule Background

ErbB3,also known as Her3 (human epidermal growth factor receptor 3), is a member of the epidermal growth factor receptor (EGFR) family of receptor tyrosine kinases. This membrane-bound glycoprotein has a neuregulin binding domain but has not an active kinase domain. It therefore can bind the ligand but cannot mediate the intracellular signal transduction through protein phosphorylation. However, it does form heterodimers with ErbB2 or other EGFR members responsible for tyrosine phosphorylation to give a receptor complex and initiate the related pathway, which lead to cell proliferation or differentiation. Overexpression of this protein has been reported in numerous cancers, including prostate, bladder, and breast tumors. This protein has different isoforms derived from alternative splicing variants, and among which, the secreted isoform lacking the intermembrane region modulates the activity of membrane-bound form.

ErbB3 References

ErbB3 Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
KTN-3379 KTN-3379; CDX-3379,KTN3379; CDX3379 Phase Ⅱ MedImmune, Kolltan Thyroid cancer, Solid tumours, Head and neck cancer Details
Allitinib Tosylate AST-6; ALS-1306; AST-1306 Phase Ⅱ Shanghai Allist Pharmaceuticals Breast cancer, Lung cancer Details
AC-480 AC-480; BMS-599626 ,AC480; BMS599626 ,AC 480; BMS 599626 Phase Ⅰ Ambit biosciences Glioma, Solid tumours Details
Patritumab AMG-888; U3-1287,AMG888,U31287 Phase Ⅲ Daiichi Sankyo, Amgen Non small cell lung cancer (NSCLC), Metastatic breast cancer Details
Recombinant Human Neuromodulin 1-Anti-HER3 Antibody Fusion Protein(Salubris) SAL-007 IND Filing Salubris Unspecified Details
SPC-3920 SPC-3920; EZN-3920 Preclinical Roche Cancer Details
Seribantumab MM-121; SAR-256212; 1N3L70MDFX (UNII code) Phase Ⅱ Merrimack, Sanofi Non small cell lung cancer (NSCLC), Breast cancer, Solid tumours, Ovarian cancer Details
Sapitinib AZD-8931 Phase Ⅱ AstraZeneca Colorectal cancer Details
ISU-104 ISU-104 Phase Ⅰ ISU Abxis Solid tumours Details
REGN-1400 REGN-1400 Phase Ⅰ Regeneron Pharmaceutical Solid tumours Details
GSK-2849330 GSK-2849330,GSK2849330 Phase Ⅰ GlaxoSmithKline Solid tumours Details
Recombinant human ErbB3 fragment vaccine (Zensun) rhErbB3-f Phase Ⅰ Zensun Solid tumours Details
Tesevatinib EXEL-7647; KD-019; KD-020; XL-647,KD019,EXEL7647,KD020,XL647 Phase Ⅲ Exelixis, Kadmon Non small cell lung cancer (NSCLC), Autosomal dominant polycystic kidney disease (ADPKD) Details
MP-0274 CME-114; SPA-28; MP-0274; CME-119; CME-118; CME-115; DARPin-41 Phase Ⅰ Molecular Partners Solid tumours Details
Elisidepsin PM-02734; PM-2734 Phase Ⅱ PharmaMar Solid tumours Details
Recombinat humanized HER3-targeting antibody Phase Ⅰ Shanghai Institute of Biological Products Solid tumours Details
Sirotinib Maleate XZP-5491,XZP5491 Phase Ⅰ XuanZhu Pharma Esophageal squamous cell carcinoma, Non small cell lung cancer (NSCLC), Gastric cancer Details
Sym-013 Sym-013 Phase Ⅱ Symphogen Cancer Details
U3-1402 U3-1402,U31402; U3 1402 Phase Ⅱ Daiichi Sankyo Non small cell lung cancer (NSCLC), Breast cancer Details
Duligotuzumab (Genentech) MEHD-7945A; RG-7597; RO-5541078,MEHD7945A; RG7597; RO5541078 Phase Ⅰ Genentech Solid tumours Details
HMBD-001 HMBD-001,MBD-001-10D1 Preclinical Hummingbird Bioscience Solid tumours Details
MM-111 MM-111 Phase Ⅱ Merrimack Gastric cancer, Esophagus cancer, Breast cancer, Solid tumours Details
Zenocutuzumab MCLA-128 Phase Ⅱ Merus Non small cell lung cancer (NSCLC), Gastric cancer, Solid tumours, Metastatic breast cancer, Ovarian cancer Details
Lumretuzumab RG-7116; RO-5479599 Phase Ⅱ Roche Non small cell lung cancer (NSCLC), Breast cancer, Solid tumours Details
Elgemtumab LJM-716; NOV-6 Phase Ⅱ MorphoSys, Novartis Gastric cancer, Esophagus cancer, Breast cancer, Solid tumours, Head and neck cancer Details
TAD011 TAD-011,TAD011; TAD 011 IND Filing TOT Biopharm Brain cancer, Colorectal cancer, Head and neck cancer, Pancreatic cancer Details
AV-203 AV-203; CAN-017,CAN017 Phase Ⅰ AVEO, CANbridge Life Sciences Solid tumours Details
Istiratumab MM-141; XLR461MD3M (UNII code) Phase Ⅱ Merrimack, Shire, Adimab Ovarian cancer, Pancreatic cancer Details
SI-B001 SI-B001 Phase Ⅰ Sichuan Baili Pharmaceutical Cancer Details

This web search service is supported by Google Inc.